FDA

➤ FDA advisory committee meets, hears public comments about atropine drop ➤ FDA requires label change on GLP-1s due to ocular risk ➤ First patient dosed in Phase 1 trial of gene therapy for Stargardt disease ➤ Preclinical program for investigational, first-in-class DED therapy complete ➤ Company aligns with FDA on Phase 3 program for Stargardt disease therapy ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week